Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Modeling immune responses to autologous and allogeneic human stem cell-derived islet grafts in vivo.

JCI insight·2026

Same author

Validation of a blood-based autoantibody test to assess lung cancer risk in 4-30 mm pulmonary nodules: a retrospective pooled analysis of four cohort studies.

Future oncology (London, England)·2026

Same author

Substituent-Based Modulation of Self-Assembly and Immunogenicity of Amphipathic Peptides.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Substituent-based Modulation of Self-Assembly and Immunogenicity of Amphipathic Peptides.

bioRxiv : the preprint server for biology·2025

Same author

COVID-19 mRNA vaccine immune response to the addition of osteopathic manipulative treatment with lymphatic pumps: a randomized controlled trial.

Virus research·2025

Same author

A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload.

Scientific reports·2025

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor.

Min Huang¹, Samadhi N Vitharana, Laura J Peek

¹Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas 66047, USA.

Biomacromolecules

|April 13, 2007

Summary

Developing new blood vessels (angiogenesis) is key for treating ischemia. Researchers created stable vascular endothelial growth factor (VEGF) nanoparticles for sustained, localized delivery, improving therapeutic potential.

More Related Videos

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Published on: August 19, 2015

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Experiment Videos

Last Updated: Jul 15, 2026

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Published on: August 19, 2015

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Area of Science:

Biomaterials Science
Nanotechnology
Vascular Biology

Background:

Angiogenesis is crucial for treating ischemic conditions.
Intravenous delivery of vascular endothelial growth factor (VEGF) has shown limited success.
Localized, sustained VEGF delivery is necessary for effective blood vessel generation.

Purpose of the Study:

To develop injectable nanosuspensions for controlled, sustained release of stabilized VEGF.
To create nanoparticles that can accumulate in target tissues and maintain local VEGF concentration.

Main Methods:

Utilized the heparin binding domain of VEGF to bind dextran sulfate, enhancing VEGF thermal stability.
Formed nanoparticles via coacervation of VEGF-bound dextran sulfate with polycations (chitosan, polyethylenimine, poly-L-lysine).
Characterized nanoparticle size, VEGF encapsulation efficiency, release kinetics, and biological activity.

Main Results:

Produced nanoparticles approximately 250 nm in diameter with high VEGF encapsulation efficiency (50-85%).
Achieved sustained VEGF release (>10 days) with maintained biological activity.
Chitosan-dextran sulfate nanoparticles demonstrated optimal properties: biodegradability, size, entrapment, controlled release, and mitogenic activity.

Conclusions:

Developed stable, injectable VEGF-loaded nanoparticles with controlled release properties.
Chitosan-dextran sulfate nanoparticles show significant promise for localized VEGF delivery in therapeutic angiogenesis.
This approach may overcome limitations of previous VEGF delivery methods for ischemic diseases.